SamanTree Medical has developed the Histolog® Scanner, a CE-marked and FDA cleared device, that enables rapid high-resolution imaging of fresh tissue surfaces during surgery. This breakthrough technology allows pathologists and surgeons to perform real-time intraoperative assessments of resected tissue, significantly faster than conventional techniques. Based on ultra-fast confocal microscopy, the Histolog Scanner has already been utilized in over 5,000 surgical procedures in prostate and breast cancer with studies in bladder, penile, lung and ENT cancer underway or being planned.
Related: CMR Surgical secures more than $200m to accelerate growth
Karista’s investment in SamanTree Medical reflects its dedication to backing pioneering medical technologies with the potential to transform healthcare. As part of this investment, Amine Benmoussa, Partner at Karista, will join SamanTree’s Board of Directors. He commented: “The Histolog Scanner represents a major advancement in intra-operative margin assessment. Its real-time, high-resolution imaging for a range of cancer types during surgery addresses a critical need in cancer care, reducing re-operation rates and improving patient outcomes. We are excited about its potential as a platform technology with broad applications, enabling more precise decision-making and setting new standards in precision surgical oncology. This investment aligns well with our ESG strategy as the Histolog Scanner exemplifies the patient-centric innovation we strive to nurture, advancing healthcare delivery and improving lives.”
This Series B extension builds upon the previous financing round announced in July 2024, led by Turenne Capital, with participation from Mutuelles Impact, Wille Finance, Noshaq, and WE Life Sciences (Wallonie Entreprendre), along with returning investors Panakès Partners, BOM, Ekwithree and others. This additional funding will accelerate commercial expansion, with a focus on scaling operations in the U.S. and strengthening SamanTree’s presence in Europe.
Chuck Carignan, Chairman of SamanTree Medical, stated: “Karista’s leadership in this round is a testament to the growing confidence in our technology and vision. As the Histolog Scanner is already making a meaningful impact in surgical oncology, this upsized financing will be further instrumental in accelerating our expansion and adoption, while advancing our mission to improve surgical outcomes. We are excited to welcome Karista’s expertise and strategic support as we enter this next phase of growth.”
Olivier Delporte, CEO of SamanTree Medical, commented : “The ongoing support of both new and returning investors underscores the remarkable progress we’ve made. Building on the exciting clinical data presented at EAU in Madrid, intraoperative margin assessment allowed for nerve-sparing prostatectomies, resulting in significantly improved erectile function and continence. Moreover, the Histolog Scanner demonstrated accuracy and clinical relevance.”
